With the revision of the Pharmaceuticals and Medical Devices Act (PMD Act) on August 1, 2021, some procedures for the pharmaceutical system of manufacturing and marketing of veterinary drugs, etc. have been changed.
Some application forms for manufacturing, manufacturing and marketing, foreign manufacturer accreditation for veterinary drugs, veterinary medical devices, in vitro diagnostic kits, etc. have been partially changed. Please be careful.
The HealthforAnimals Global Benchmarking Survey is run every 5 years and has now grown to include 11 countries in the 2020 survey. The purpose is to examine the interactions between industry and regulatory systems for veterinary medicinal products, particularly the impact of regulations on the animal health industry’s ability to access markets, be innovative, continue to commercialise existing products and be competitive.
Osaka-based Senju Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, President: Shuhei Yoshida, hereinafter “Senju Pharmaceutical”) and DS Pharma Animal Health Co., Ltd. will release “IDU Senju (R) “, an eye drops for cat herpesvirus infections, which Senju Pharmaceutical obtained marketing approval in December 2020, and will release it on May 19, 2021.
DS Pharma Animal Health Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; President & CEO: Kazuhiro Takada) announced today that it received marketing authorization on March 19 for Stemcure® (development code: A-110), a canine allogeneic adipose tissue-derived mesenchymal stem cell product that is classified as a veterinary regenerative medical product (animal somatic stem cell-processed product). This is the world’s first authorization approval for the manufacture and marketing of a veterinary regenerative medical product whose main ingredient is canine allogeneic adipose tissue-derived mesenchymal stem cells.
Thanks to Kisaco Research, the two pre-events of Animal Health Innovation Asia 2020 were successfully conducted on November 3rd and 10th. According to Mr. Stephen Swarray of Kisaco, 300 people joined the pre-event “Next Steps for Animal Health in Asia” by Zoetis. Of course, I really enjoyed both, too.
The captioned article has been written by Dr. Yuki Ujimasa, DVM, MS, President of AHRMS, Inc., and published on the Journal of the Japan Veterinary Medical Association since October 2019. It recently became public via the following link: http://nichiju.lin.gr.jp/mag/07210/a4.pdf Sorry to say, it is described only in Japanese. The chapters of the article are as follows: 1. Recent activities by multi-national animal health pharmaceutical companies and domestic companies 2. New technologies that can change husbandry industries 3. Impact of emerging and re-emerging infectious diseases in food animals and Possibilities of plant-based meat and cultured meat 4. Telemedicine in veterinary medicines 5. Changes of distribution system and home-delivery in companion animal medicines 6. Necessity for review of veterinary advertising regulations 7. Conclusions 8. Acknowledgment